Japanese regulatory approval of sorafenib for liver cancer

Bayer HealthCare and Onyx Pharmaceuticals Inc. announced on May 20 to have received Japanese regulatory approval of their drug candidate Nexavar (sorafenib) as a treatment for advanced liver cancer. The approval means Nexavar can be marketed for the most common type of liver cancer, hepatocellular carcinoma. In addition the drug is already approved in Japan as a treatment for kidney cancer.